American Journal of Cancer Research, Feb. 2018: "Ivermectin has PROVEN anti-tumor activity"

Ivermectin showed massive positive results on Leukemia, Breast, Colon, Ovarian, Glioma and Glioblastoma Cancers:

"Conclusions:

The recognition that drug repositioning is a clever opportunity to accelerate the development of cancer drugs is increasing. So far, at least 235 clinically-approved, non-cancer drugs have proven antitumor activity either in vitro, in vivo, or even clinically. Among these, ivermectin, an antiparasitic compound of wide use in veterinary and human medicine, is clearly a strong candidate for repositioning, based on the fact that i) it is very safe, causing almost no side-effects other than those caused by the immune and inflammatory responses against the parasite in infected patients, and ii) it has proven antitumor activity in preclinical studies. On the other hand, it is now evident that the use of very selective 'unitargeted' drugs is commonly associated to early development of resistance by cancer cells, hence the use of 'dirty' or 'multitargeted' drugs is important to explore. In this sense, ivermectin has this potential as it modulates several targets such as the multidrug resistance protein (MDR), the Akt/mTOR and WNT-TCF pathways, the purinergic receptors, the PAK-1 protein, certain cancer-related epigenetic deregulators such as SIN3A and SIN3B, RNA helicase activity, while stimulates chloride channel receptors leading to cell hyperpolarization, and down-regulates stemness genes to preferentially target cancer stem-cell like population, at least in breast cancer. Importantly, the in vitro and in vivo antitumor activities of ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies done in healthy and parasited patients. Thus, existing information on ivermectin could allow its rapid move into clinical trials for cancer patients."

[link to www.ncbi.nlm.nih.gov (secure)]

:mred19:

:trickydick19: